Jeffrey Cohen talks to us about proposed new updates to the McDonald criteria for MS diagnosis.
1. Why are revisions to the McDonald criteria needed? (0:05)
2. What are the limitations of the current criteria in special populations (i.e. paediatric, Asian and Latin American people)? (0:38)
3. What revisions have been proposed to the definition of MS phenotypes? (1:11)
4. How have the revisions reflected the increased value of CSF in diagnosis of MS? (2:23)
5. What revisions have been made to the MRI criteria for the diagnosis of MS? (3:46)
Speaker disclosures: Jeffrey Cohen serves as a consultant to Adamas and Celgene, and as Co-Editor of Multiple Sclerosis Journal – Experimental, Translational and Clinical.
Filmed at the 7th Joint ECTRIMS-ACTRIMS Meeting, Paris, France, October 2017.
Share this Video
Related Videos In Multiple Sclerosis
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!